Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chula Vista, California 91910


Purpose:

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.


Criteria:

Inclusion Criteria: - Have been diagnosed with prostate cancer. - Have a rising PSA while on hormone therapy or following surgical castration. Exclusion Criteria: - Have evidence of distant metastatic disease on screening bone scan or CT scan. - Have received cytotoxic chemotherapy. - Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.


NCT ID:

NCT00036556


Primary Contact:

Study Director
Gary Gordon, M.D.
Abbott


Backup Contact:

N/A


Location Contact:

Chula Vista, California 91910
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.